CAM
FRTX

ClariVest Asset Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

ClariVest Asset Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-224
Closed -$215K – 736
2016
Q3 		$215K Buy
224
+78
+53% +$98.4K 0.01% 485
2016
Q2 		$208K Buy
+146
New +$188K 0.01% 464

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ClariVest Asset Management's FRTX Position: Q4 2016 in Review

ClariVest Asset Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2016, closing a stake of 224 shares — an estimated $215K sold.

ClariVest Asset Management first reported a position in FRTX in Q2 2016 and held it in 2 quarters. The position peaked at $215K in Q3 2016. 26 funds tracked by Wall St. Rank hold FRTX as of Q4 2016.

  • ClariVest Asset Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • ClariVest Asset Management sold 224 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $215K.
  • ClariVest Asset Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2016 and held it in 2 quarters.
  • ClariVest Asset Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $215K in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2016.

Based on ClariVest Asset Management's 13F filing for Q4 2016, filed 10 Feb 2017.